

Literatur zum Artikel:

Polymedikation und Deprescribing bei älteren Menschen

Polypharmazie und potenziell inadäquate Medikamente

von Dr. med. Johannes Trabert und PD Dr. med. Rupert Püllen

- [1] Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. *Fam Pract.* 2007; 24(1):14–19. doi: 10.1093/fampra/cml067
- [2] Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. *Expert Opin Drug Saf.* 2014; 13(1):57–65. doi: 10.1517/14740338.2013.827660
- [3] Pazan F, Weiss C, Wehling M; FORTA. The FORTA (Fit FOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults [published correction appears in *Drugs Aging.* 2022 Jun; 39(6):485]. *Drugs Aging.* 2022; 39(3):245–247. doi: 10.1007/s40266-022-00922
- [4] Mühlbauer B. The New PRISCUS List. *Dtsch Arztebl Int.* 2023; 120(1–2): 1–2. doi: 10.3238/arztebl.m2022.0408
- [5] Amann U, Schmedt N, Garbe E. Prescribing of potentially inappropriate medications for the elderly: an analysis based on the PRISCUS list. *Dtsch Arztebl Int.* 2012; 109(5):69–75. doi: 10.3238/arztebl.2012.0069
- [6] Lim J, Jeong S, Jang S, Jang S. Hospitalization and emergency department visits associated with potentially inappropriate medication in older adults: self-controlled case series analysis. *Front Public Health.* 2023; 11: 1080703. Published 2023 Jun 30. doi:10.3389/fpubh.2023.1080703
- [7] Pazan F, Breunig H, Weiss C, et al. Higher FORTA (Fit FOR The Aged) scores are associated with poor functional outcomes, dementia, and mortality in older people. *Eur J Clin Pharmacol.* 2022; 78(11):1851–1859. doi: 10.1007/s00228-022-03389-w
- [8] Krüger C, Schäfer I, van den Bussche H, et al. Non-random relations in drug use expressed as patterns comprising prescription and over-the-counter drugs in multimorbid elderly patients in primary care: Data of the exploratory analysis of the multicentre, observational cohort study MultiCare. *Eur J Gen Pract.* 2021; 27(1):119–129. doi:10.1080/13814788.2021.1933425
- [9] Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ.* 2005; 173(5): 489–495. doi: 10.1503/cmaj.050051
- [10] Randles MA, O'Mahony D, Gallagher PF. Frailty and Potentially Inappropriate Prescribing in Older People with Polypharmacy: A Bi-Directional Relationship? *Drugs Aging.* 2022; 39(8): 597–606. doi:10.1007/s40266-022-00952-z
- [11] Chou YY, Lee YS, Lin CS, et al. Gender-specific linkages: frailty, polypharmacy, anti-cholinergic burden, and 5-year mortality risk—a real-world analysis. *PeerJ.* 2023; 11: e16262. Published 2023 Nov 21.
- [12] Welsh TJ, McGrogan A, Mitchell A. Deprescribing in the last years of life—it's hard to STOPP. *Age Ageing.* 2020; 49(5): 723–724. doi: 10.1093/ageing/afaa081
- [13] Lee J, Negm A, Peters R, Wong EKC, Holbrook A. Deprescribing fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis. *BMJ Open.* 2021;11(2):e035978. Published 2021 Feb 10. doi: 10.1136/bmjopen-2019-035978
- [14] Egberts A, Moreno-Gonzalez R, Alan H, Ziere G, Mattace-Raso FUS. Anticholinergic Drug Burden and Delirium: A Systematic Review. *J Am Med Dir Assoc.* 2021;22(1):65–73.e4. doi: 10.1016/j.jamda.2020.04.019
- [15] Kao AC, Nanda A, Williams CS, Tinetti ME. Validation of dizziness as a possible geriatric syndrome. *J Am Geriatr Soc.* 2001;49(1):72–75. doi:10.1046/j.1532-5415.2001.49012.x
- [16] Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. *Arch Intern Med.* 2010; 170(18):1648–1654. doi: 10.1001/archinternmed.2010.355

Literatur zum Artikel:

Infektionskrankheiten im höheren Lebensalter

von PD Dr. med. Sandra Schütze und Dr. med. Oliver Habich

- [1] Spector W et al. (2012) Transitions between nursing homes and hospitals in the elderly population. Healthcare cost and utilization project (HCUP), Statistical Brief #141. Agency for Healthcare Research and Quality, Rockville (MD).
- [2] Ewig S et al. (2009) New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. *Thorax* 64: 1062–1069.
- [3] Esme M et al. (2019) Infections in the elderly critically-ill patients. *Front Med* 6: 118.
- [4] Brown JD et al. (2018) The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. *BMC Geriatr* 18: 92.
- [5] Werner J, Kuntsche J (2000) Infection in the elderly – what is different? *Z Gerontol Geriatr* 33: 350–356.
- [6] Ewig S et al. (2016) Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016. S3-Leitlinie 2016.
- [7] Huang W et al. (2019) Functional impairment and serum albumin predict in-hospital mortality in nonagenarians with acute infection: a retrospective cohort study. *BMC Geriatrics* 19: 269.
- [8] Briongos-Figuero LS et al. (2015) In-hospital mortality due to infectious disease in an Internal Medicine Department. *Epidemiology and risk factors. Eur Rev Med Pharmacol* 19: 567–572.
- [9] El Chakhtoura NG et al. (2017) Influence of aging and environment on presentation of infection in older adults. *Infect Dis Clin North Am* 31: 593–608.
- [10] Del Giudice G et al. (2017) Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging. *NPJ Aging Mech Dis* 4:1.
- [11] Walford RL (1969) Immunologic aspects of aging. *Klin Wochenschr* 47: 599–605.
- [12] Gavazzi G, Krause KH (2002) Ageing and infection. *Lancet Infect Dis* 2: 659–666.
- [13] Ventura MT et al. (2017) Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. *Clin Mol Allergy* 15: 21.
- [14] Franceschi C et al. (2018) Inflammaging: a new immune-metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol* 14: 576–590.
- [15] Yoshikawa TT, Norman DC (2017) Geriatric infectious diseases: current concepts on diagnosis and management. *J Am Geriatr Soc* 65: 631–641.
- [16] Pasini E et al. (2018) Protein-amino acid metabolism disarrangements: the hidden enemy of chronic age-related conditions. *Nutrients* 10.
- [17] Aiello A et al. (2019) Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. *Front Immunol* 10: 2247.
- [18] Recinella G et al. (2020) Prognostic role of nutritional status in elderly patients hospitalized for COVID-19: a monocentric study. *Aging Clin Exp Res* 32: 2695–2701.
- [19] Bordoni B et al. (2020) Ageing of the diaphragm muscle. *Cureus* 12(1): e6645.
- [20] Baijens LW et al. (2016) European Society for Swallowing Disorders – European Union Geriatric Society white paper: oropharyngeal dysphagia as a geriatric syndrome. *Clin Interv Aging* 11: 1403–1428.
- [21] Tagliaferri S et al. (2019) The risk of dysphagia is associated with malnutrition and poor functional outcomes in a large population of outpatient older individuals. *Clin Nutr* 38: 2684–2689.
- [22] Serra-Prat M et al. (2012) Oropharyngeal dysphagia as a risk factor for malnutrition and lower respiratory tract infection in independently living older persons: a population-based prospective study. *Age Ageing* 41: 376–381.
- [23] Tralhao A, Povoas P (2020) Cardiovascular events after community-acquired pneumonia: a global perspective with systematic review and meta-analysis of observational studies. *J Clin Med* 9(2).
- [24] Patrick et al. (2019) Exploring the „Multiple-Hit-Hypothesis“ of neurodegenerative disease: bacterial infection comes up to bat. *Front Cell Infect Microbiol* 9: 138.
- [25] Linden D et al. (2019) Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD. *Eur Respir Rev* 28: 151.

- [26] Holmes C et al. (2009) Systemic inflammation and disease progression in Alzheimer disease. *Neurology* 73: 768–774.
- [27] Koay L et al. (2017) Factors that lead to hospitalisation in patients with Parkinson disease: a systematic review. *Int J Clin Pract* 72(1).
- [28] Perry VH et al. (2003) The impact of systemic infection on the progression of neurodegenerative disease. *Nat Rev Neurosci* 4: 103–112.
- [29] Schütze S et al. (2012) Additive microglia-mediated neuronal injury caused by amyloid- β and bacterial TLR agonists in murine neuron-microglia co-cultures quantified by an automated image analysis using cognition network technology. *J Alzheimer's Dis* 31: 651–657.
- [30] Kale SS, Yende S (2011) Effects of aging on inflammation and hemostasis through the continuum of critical illness. *Aging and Disease* 2: 501–411.
- [31] Beckett CL et al. (2015) Special considerations of antibiotic prescription in the geriatric population. *Clin Microbiol Infect* 21: 3–9.
- [32] Schütze S et al. (2023) Septic encephalopathy in the elderly – biomarkers of potential clinical utility. *Frontiers in Cellular Neuroscience* 17: 1238149.
- [33] McCormick R, Vasilaki A (2018) Age-related changes in skeletal muscle: changes to life-style as a therapy. *Biogerontology* 19: 519–536.
- [34] High KP et al. (2009) Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. *J Am Geriatr Soc* 57: 375–394.
- [35] Gomolin IH et al. (2005) Older is colder: temperature range and variation in older people. *J Am Geriatr Soc* 53: 2170–2172.
- [36] Norman DC (2016) Clinical features of infection in older adults. *Clin Geriatr Med* 32: 433–441.
- [37] Sloane PD et al. (2014) Role of body temperature in diagnosing bacterial infection in nursing home residents. *J Am Geriatr Soc* 62: 135–140.
- [38] Henning DJ et al. (2017) The absence of fever is associated with higher mortality and decreased antibiotic and iv fluid administration in emergency department patients with suspected septic shock. *Crit Care Med* 45: e575–e582.
- [39] Schütze S et al. (2014) Higher mortality and impaired elimination of bacteria in aged mice after intracerebral infection with *E. coli* are associated with an age-related decline of microglia and macrophage functions. *Oncotarget* 5: 12573–12592.
- [40] Metcalf TU et al. (2015) Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. *Aging Cell* 14: 421–432.
- [41] Blatteis CM (2012) Age-dependent changes in temperature regulation – a mini review. *Gerontology* 58: 289–295.
- [42] Welte T (2011) Community-acquired pneumonia: a disease of the elderly. *Z Gerontol Geriatr* 44: 221–228.
- [43] Cillóniz C et al. (2018) Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging *Med Sci* 6.
- [44] Warmerdam M et al. (2017) Initial disease severity and quality of care of emergency department sepsis patients who are older or younger than 70 years of age. *PLoS One* 12: e0185214.
- [45] Michener A et al. (2018) Infections in Older Adults: A Case-Based Discussion Series Emphasizing Antibiotic Stewardship. *MedEdPORTAL* 14: 10754.
- [46] Gbinigie OA et al. (2019) Biomarkers for diagnosing serious bacterial infections in older outpatients: a systematic review. *BMC Geriatr* 19: 190.
- [47] Ticinesi A et al. (2017) C-reactive protein (CRP) measurement in geriatric patients hospitalized for acute infection. *Eur J Intern Med* 37: 7–12.
- [48] van Vught LA et al. (2014) The effect of age on the systemic inflammatory response in patients with community-acquired pneumonia. *Clin Microbiol Infect* 20: 1183–1188.
- [49] Higashikawa T et al. (2018) Procalcitonin and albumin as prognostic biomarkers in elderly patients with a risk of bacterial infection. *J Int Med Res* 46: 2606–2614.
- [50] Schuetz P et al. (2019) Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. *Clin Chem Lab Med* 57: 1308–1318.
- [51] Rossio R et al.; REPOSI Investigators (2015) Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. *Eur J Intern Med* 26: 330–337.
- [52] De With K et al. (2018) Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus – update 2018. S3-Leitlinie der Deutschen Gesellschaft für Infektiologie (DGI, federführend); AWMF-Registernummer 092–001.
- [53] Jump RLP et al. (2018) Infectious diseases in older adults of long-term care facilities: update on approach to diagnosis and management. *J Am Geriatr Soc* 66: 789–803.

- [54] Gruber I et al. (2013) Multidrug-resistant bacteria in geriatric clinics, nursing homes, and ambulant care – prevalence and risk factors. *Int J Med Microbiol* 303: 405–409.
- [55] Katz MJ et al. (2017) Implementing Antimicrobial Stewardship in Long-term Care Settings: An Integrative Review Using a Human Factors Approach. *Clin Infect Dis* 65: 1943–1951.
- [56] Draenert R, Jung N; Choosing Wisely (Klug entscheiden) DGI Working Group (2020) Update on the „Choosing Wisely“ initiative in infectious diseases in Germany. *Infection* 48:317–321.
- [57] Loizeau AJ et al. (2019) The trial to reduce antimicrobial use in nursing home residents with Alzheimer’s disease and other dementias: study protocol for a cluster randomized controlled trial. *Trials* 20: 594.
- [58] Lode H (2010) Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. *Am J Med* 123: 26–38.
- [59] Bodmann KF et al. (2019) S2k Leitlinie: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018; AWMF-Registernummer 082–006. Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. (PEG) (Hrsg.).
- [60] Goldenberg JZ et al. (2018) Probiotics to prevent *Clostridium difficile* enteritis in patients receiving antibiotics. *JAMA* 320: 499–500.
- [61] Volkert D et al. (2019) ESPEN Guideline on clinical nutrition and hydration in geriatrics. *Clinical Nutrition* 38: 10–47.
- [62] Li J et al. (2019) Nursing resources and major immobility complications among bedridden patients: a multicenter descriptive study in China. *J Nurs Manag* 27: 930–938.
- [63] Wong GCL et al. (2019) Hallmarks of improved immunological responses in the vaccination of more physically active elderly females. *Exerc Immunol Rev* 25: 20–33.
- [64] Nilsson MI et al. (2019) Lifelong aerobic exercise protects against inflammaging and cancer. *PLoS One* 14: e0210863.
- [65] Krüger K et al. (2016) The immunomodulatory effects of physical activity. *Curr Pharm Des* 22: 3730–3748.
- [66] Pape K et al. (2016) Leisure-Time Physical Activity and the Risk of Suspected Bacterial Infections. *Med Sci Sports Exerc* 48: 1737–1744.
- [67] Drey et al. (2018) Sarkopenie. In: Maetzler W, Dodel R, Jabobs AH J (Hrsg.) *Neurogeriatrie*. Berlin: Springer. S. 69–84.
- [68] Doherty TM et al. (2019) Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion. *Ann Med* 51: 128–140.
- [69] Esposito S et al. (2018) The public health value of vaccination for seniors in Europe. *Vaccine* 36: 2523–2528.
- [70] Burke M, Rowe T (2018) Vaccinations in older adults. *Clin Geriatr Med* 34: 131–143.
- [71] Robert Koch-Institut (RKI) (2024) Empfehlungen der Ständigen Impfkommission (STIKO). *Epidemiologisches Bulletin* 4/24.

Literatur zum Artikel:

Neue krankheitsmodifizierende Therapien für Alzheimer: Kurz vor der europäischen Zulassung?

von Prof. Dr. med. Johannes Pantel

- [1] Pantel J. Alzheimer-Demenz von Auguste Deter bis heute : Fortschritte, Enttäuschungen und offene Fragen. *Z Gerontol Geriatr.* 2017 Oct;50(7):576–587. German. doi: 10.1007/s00391–017–1307–2. Epub 2017 Sep 18. PMID: 28924872.
- [2] Dhillon S. Aducanumab: First Approval. *Drugs.* 2021 Aug; 81(12):1437–1443. doi:10.1007/s40265–021–01569-z. Erratum in: *Drugs.* 2021 Sep;81(14):1701. PMID: 34324167.
- [3] Alzheimer Forschung Initiative. Neuer Alzheimer-Wirkstoff Aducanumab – der neueste Stand. 7.05.2024. <https://www.alzheimer-forschung.de/forschung/aktuell/aducanumab/> (abgerufen am 28.05.2024).
- [4] van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. *N Engl J Med.* 2023 Jan 5;388(1):9–21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. PMID: 36449413.
- [5] Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA.* 2023 Aug 8; 330(6):512–527.
- [6] Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. *Alzheimers Res Ther.* 2024 May 10;16(1):105. doi: 10.1186/s13195–024–01441–8. PMID: 38730496; PMCID: PMC11084061.
- [7] Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S. Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimers Dis.* 2023; 10(3):362–377. doi: 10.14283/jpad.2023.30
- [8] Ebell MH, Barry HC, Baduni K, Grasso G. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis. *Ann Fam Med.* 2024 Jan-Feb;22(1):50–62. doi: 10.1370/afm.3050. PMID: 38253509.

Literatur zum Artikel:

Die Beihilfe zur Selbsttötung: Bald doch eine ärztliche Tätigkeit?

von Prof. Dr. iur. utr. Carsten Schütz und Dr. med. Thomas Sitte

- [1] BGH Urteil vom 25.6.2010 2 StR 454/09.
- [2] BGH, Beschluss vom 17.9.2014 – XII ZB 202/13.
- [3] BVerwG Urteil vom 2.3.2017 (3 C 19.15).
- [4] BVerwG Urteil vom 2. 3.2017 (3 C 19.15 = NJW 2017, 2215 ff., m. Anm. Schütz/Sitte, ausf. dies., Rechtsmedizin 2018, 104 ff.
- [5] BVerfG Urteil vom 26. Februar 2020 (2 BvR 2347/15 u. a).
- [6] BVerwG Urteil vom 07.11.2023(3 C 8.22 u. a.).
- [7] Art. 2 Abs. 1 i.V.m. Art. 1 Abs. 1 GG
- [8] Putz, Wolfgang; de Ridder, Michael: Die aktuelle Rechtsprechung und die Suizidhilfe – Legale Mittel und legale Wege aus strafrechtlicher und pharmakologischer Sicht. In: *humanes leben humanes sterben*, 2024–2, S. 9–11. https://www.dghs.de/fileadmin/content/05_aktuelles/magazin/pdfs/HLS_2024-2_gesamt.pdf oder via Kurzlink: <https://tinyurl.com/3hykdbdn>
- [9] Roßbruch, Robert: Freitodbegleitung: Die neuen Zahlen – DGHS-Pressekonferenz zu Suizidhilfe-Bilanz 2023 und der Rolle der Ärzt:innen. In: *humanes leben humanes sterben*, 2024–2, Jahrgang 44, S. 4; https://www.dghs.de/fileadmin/content/05_aktuelles/magazin/pdfs/HLS_2024-2_gesamt.pdf oder via Kurzlink: <https://tinyurl.com/3hykdbdn>
- [10] Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733–42.
- [11] Sitte T, Gronwald B, Gottschling S. Leidenslinderung und Symptomkontrolle Eine Umfrage unter Palliativmedizinern zum ärztlich assistierten Suizid und zur Tötung auf Verlangen *Deutsches Ärzteblatt* 2015;112: 1614–16
- [12] Podiumsdiskussion mit Markus Weinberg MdB et aliter am 13.10.2014 in Hamburg, Altona